- Home
- BAP vs RPRX Comparison
BAP vs RPRX Comparison
Compare BAP & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAP
- RPRX
- Stock Information
- Founded
- BAP 1889
- RPRX 1996
- Country
- BAP Peru
- RPRX United States
- Employees
- BAP N/A
- RPRX N/A
- Industry
- BAP Major Banks
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- BAP Finance
- RPRX Health Care
- Exchange
- BAP Nasdaq
- RPRX Nasdaq
- Market Cap
- BAP 21.1B
- RPRX 16.2B
- IPO Year
- BAP 1995
- RPRX 2020
- Fundamental
- Price
- BAP $259.01
- RPRX $38.51
- Analyst Decision
- BAP Buy
- RPRX Strong Buy
- Analyst Count
- BAP 6
- RPRX 3
- Target Price
- BAP $245.00
- RPRX $46.00
- AVG Volume (30 Days)
- BAP 242.5K
- RPRX 3.2M
- Earning Date
- BAP 11-13-2025
- RPRX 11-05-2025
- Dividend Yield
- BAP 4.25%
- RPRX 2.28%
- EPS Growth
- BAP 26.90
- RPRX N/A
- EPS
- BAP 22.19
- RPRX 1.75
- Revenue
- BAP $5,576,317,301.00
- RPRX $2,349,844,000.00
- Revenue This Year
- BAP $24.87
- RPRX $36.16
- Revenue Next Year
- BAP $7.51
- RPRX $2.04
- P/E Ratio
- BAP $11.67
- RPRX $22.00
- Revenue Growth
- BAP 20.05
- RPRX 3.70
- 52 Week Low
- BAP $165.51
- RPRX $24.05
- 52 Week High
- BAP $280.88
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- BAP 49.55
- RPRX 56.61
- Support Level
- BAP $254.10
- RPRX $36.03
- Resistance Level
- BAP $263.01
- RPRX $41.24
- Average True Range (ATR)
- BAP 4.67
- RPRX 1.17
- MACD
- BAP 0.25
- RPRX 0.28
- Stochastic Oscillator
- BAP 57.35
- RPRX 48.17
About BAP Credicorp Ltd.
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.